Failure to Complete Routine AIMS Assessments for Residents on Antipsychotic Medications
Penalty
Summary
The facility failed to ensure that Abnormal Involuntary Movement Scale (AIMS) assessments were routinely completed for residents receiving antipsychotic medications. Record reviews for five sampled residents revealed that none had current or consistently completed AIMS assessments documented in their electronic medical records. These residents had various diagnoses, including schizophrenia, Alzheimer's disease, dementia, and depression, and were prescribed antipsychotic medications such as risperidone, olanzapine, and quetiapine. In some cases, the last AIMS assessment was completed several months prior, while in others, there was no evidence of any AIMS assessment being performed since admission. Interviews with facility staff confirmed the lack of routine AIMS assessments. The lead resident care manager stated that AIMS assessments should be completed upon admission, quarterly, and with any significant change in status, but acknowledged that recent assessments could not be found for residents on psychotropic medications. The MDS coordinator also confirmed that no AIMS assessments had been completed upon admission or during the MDS process. Additionally, the facility did not have a psychotropic medication policy in place and was unable to provide one for review.